Under the trend of innovation, CRO leading enterprises are expected to benefit in the long term

"Pharmaceutical network market analysis" for a long time, collection and national health insurance catalog adjustment and other policies are constantly pushing pharmaceutical companies to innovate, so that enterprises to increase research and development investment gradually become a basic requirement.
and innovation boom in China continues to ferment, enterprise research and development pipeline into the cash period at the same time, the CXO industry has also begun to usher in huge opportunities for development.
It is understood that the CXO industry includes CRO/CMO/CDMO, that is, contract research and development service organizations, contract production business organizations, contract research and development and production business organizations, through the form of contract outsourcing, to accept the pharmaceutical enterprises or biotechnology companies commissioned, in the drug research and development process to provide specialized research and development services, to provide products needed for process development, API and intermediate production, preparation production.
, 260 pharmaceutical companies had completed their first-half annual reports as of August 30, according to data.
, 10 key CXO companies' total revenue growth in 2020H1 was 25.16% and total home-owned net profit growth was 89.52%.
, the industry believes that with the domestic outbreak control is good, significant technological progress, the global competitive advantage is prominent, outsourcing market share is expected to continue to improve in the short term.
In fact, benefiting from the continued high growth of global investment in new drug research and development, affected by cost and other factors, overseas research and development outsourcing demand continues to shift to the Asia-Pacific region, domestic pharmaceutical policy forced pharmaceutical companies to increase investment in innovative research and development, and other reasons, in recent years, the domestic CXO industry is continuing to improve the business climate.
background, domestic CRO leading enterprises are expected to benefit in the long term.
, the author combed the first half of the operating income of more than 1 billion CRO leading enterprises, and we share the specific situation of its performance.
on August 13th, Drug Mingkang issued an interim results announcement.
the first half of this year, Pharmaceutical Mingkang's revenue was RMB7,231 million, up 22.68 percent year-on-year, while net profit attributable to shareholders of listed companies was RMB1,717 million, up 62.49 percent year-on-year.
are as follows: China's laboratory services revenue increased by 26.5% to 3.780 billion yuan, CDMO/CMO services revenue increased by 25.8% to 2.162 billion yuan, U.S. regional laboratory services revenue increased by 10.1% to 782 million yuan, and clinical research and other CRO services revenue increased by 5.9% to 500 million yuan.
industry analysis believes that as the overseas outbreak remains serious, Drug Mingkang will further promote global market share, the company's continuous expansion of production capacity coupled with potential merger opportunities will provide strong support for its long-term supply.
on August 26, Kanglonghuacheng released its 2020 half-year results report, which said that in the first half of 2020, the company achieved net income attributable to shareholders of listed companies of about 479 million yuan, up 196.89 percent year-on-year;
KangLongHuaCheng said in the announcement, the current overseas epidemic is becoming increasingly serious, in order to promote overseas pharmaceutical companies to seek China's CXO enterprise cooperation, pharmaceutical research and development and production outsourcing penetration rate further improved, industrial transfer further accelerated, the company may benefit from the industrial transfer trend, as well as the company's business development accelerated, so that the performance of high-speed growth.
Pharmaceuticals Tyger Pharmaceuticals achieved revenue of 1.452 billion yuan in the first half of 2020, net profit attributable to the mother of 999 million, net profit attributable to non-attribution of 303 million.
Q2 single-quarter revenue of 802 million yuan, attributable net profit of 744 million yuan, non-attributed net profit of 188 million yuan.
, tag medicine in the field of clinical CRO leadership position is stable, although the short-term health events, but in the medium and long term there is still a strong growth potential.
2020 half-year results on August 7th.
report showed that the company's net profit attributable to shareholders of listed companies in the first half of the year was about 316 million yuan, up 37.63 percent year-on-year, and operating income was about 1.266 billion yuan, up 15.81 percent year-on-year.
revenue was 790 million yuan in the second quarter, up 28.20 percent year-on-year.
the main performance drivers for the reporting period, Kalein said it was mainly due to three factors: first, faster growth in orders from Kalein and multinational pharmaceutical companies in the US and Europe.
, the domestic CDMO business into the harvest period.
addition, there is a steady increase in the gross margin of Kailai Ying.